Navigation Links
Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
Date:4/17/2008

egenerative therapies including bone repair. The Company has a robust molecular imaging development program targeting diagnosis of Parkinson's disease and potentially dementia and ADHD. The Company's lead molecular imaging product candidate is ALTROPANE which is in Phase III clinical trials for the diagnosis of Parkinsonian Syndromes including Parkinson's Disease. The Company has research collaborations with Harvard Medical School and Children's Hospital Boston.

Forward-Looking Statements

The foregoing release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward- looking statements include statements regarding Alseres Pharmaceuticals' future expectations, beliefs, intentions, goals, strategies, plans or prospects regarding the future, including the development and commercialization of ALTROPANE and CETHRIN, the prospects of the Company's CNS and regenerative therapeutics program, the Company's strategies to develop and commercialize axon regeneration technologies and the breadth of the Company's technologies and intellectual property portfolio. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including those risks, uncertainties and factors referred to in the Company's Annual Report on Form 10-K for the year ended December 31, 2007 filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Alseres Pharmaceuticals from time to time with the Securities and Exchange Commission. As a result of such risks, uncertain
'/>"/>

SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Alseres Pharmaceuticals Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial
2. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
3. Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
4. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... AUSTIN, Texas , Jan. 14, 2014  Luminex ... it expects to report results for the fourth quarter ... release announcing the results is scheduled for release after ... http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) Management will hold a conference ... for the fourth quarter and twelve months ended December ...
(Date:1/14/2014)... , Jan. 14, 2014 /PRNewswire-iReach/ -- Acumed,s new ... targeting guide with accompanying instrumentation to place and insert ... to the soft tissue (e.g. ligament) repair or reconstruction ... repair heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) ... the anatomical reduction (spacing) of the scaphoid and lunate ...
(Date:1/14/2014)... 2014   Oligomerix, Inc. , a privately ... therapeutics for Alzheimer,s disease (AD) and related neurodegenerative ... headquarters to Valhalla, NY ... agreement for additional laboratory space at New York ... on the development of small molecule drugs aimed ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... August 27 , - Oralair(R) Grasses 300IR Highly ... Allergen Challenge Chamber, Stallergenes S.A. announces the highly ... Challenge Chamber (ACC)., The study on Oralair(R) Grasses ... different treatment durations: 1 week, 1 month,2 and 4 ...
... INDIANAPOLIS, Aug. 26 Semafore Pharmaceuticals Inc.,announced data ... in Cancer in Washington, D.C., showing additional antiangiogenic,activity ... both VEGF and Bv8 signaling., PI3K is ... /mTOR pathway that,has been shown to play a ...
Cached Medicine Technology:Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber 2Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber 3SF1126, Semafore's PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines 2SF1126, Semafore's PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines 3
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... 1 More than 125 leaders,from throughout the ... joined,together to support a multi-year, statewide campaign to ... campaign, launched by Nemours Health,and Prevention Services (NHPS), ... health professionals, parents, and other leaders to,improve the ...
... Team will develop "probes" to aid in the ... 1 Southern Research,Institute --- a not-for-profit organization ... of preclinical drug discovery and drug development --,today ... Institute of,Mental Health (NIMH) to identify small molecules ...
... GARDNER, Mass., Oct. 1 Precision Optics,Corporation, Inc. (OTC ... the fourth quarter and fiscal year ended,June 30, 2007. ... the quarter ended June 30, 2007, revenues were,$1,111,833 compared ... increase,of 94%. This represents the highest quarterly revenue in ...
... Oct. 1 Mylan Laboratories Inc.,(NYSE: MYL ) ... Vice,President and Treasurer, effective October 22, 2007. Mr. Byala ... with responsibility for,treasury planning in both New York and ... in various treasury positions of increasing responsibility.,Prior to Pfizer, ...
... Oct. 1 A healthy diet and,good nutrition are ... The Pennsylvania Dental Association (PDA) stresses the,importance of watching ... Think of your body as a complex machine. The ... up" affect your general health and that of your,teeth ...
... 1 Bally Total Fitness announced,that it has ... private company,just over two months after filing for ... funded by Harbinger Capital Partners,Master Fund I, Ltd. ... became effective today. Harbinger invested approximately $233.6 ...
Cached Medicine News:Health News:More than 125 State Leaders - Including Governor, Lt. Governor, and Congressional Delegation - Endorse Campaign to Make Delaware's Kids the Healthiest in the Nation 2Health News:More than 125 State Leaders - Including Governor, Lt. Governor, and Congressional Delegation - Endorse Campaign to Make Delaware's Kids the Healthiest in the Nation 3Health News:Southern Research Institute's Neurodegenerative Disease Drug Discovery Program Receives National Institute of Mental Health Funding 2Health News:Southern Research Institute's Neurodegenerative Disease Drug Discovery Program Receives National Institute of Mental Health Funding 3Health News:Precision Optics Corporation Announces Fourth Quarter and Year End Results With Highest Revenues in Six Years 2Health News:Precision Optics Corporation Announces Fourth Quarter and Year End Results With Highest Revenues in Six Years 3Health News:Precision Optics Corporation Announces Fourth Quarter and Year End Results With Highest Revenues in Six Years 4Health News:Precision Optics Corporation Announces Fourth Quarter and Year End Results With Highest Revenues in Six Years 5Health News:Precision Optics Corporation Announces Fourth Quarter and Year End Results With Highest Revenues in Six Years 6Health News:Precision Optics Corporation Announces Fourth Quarter and Year End Results With Highest Revenues in Six Years 7Health News:Precision Optics Corporation Announces Fourth Quarter and Year End Results With Highest Revenues in Six Years 8Health News:Mylan Announces Appointment of Brian Byala as Senior Vice President and Treasurer 2Health News:PDA Stresses Importance of Good Nutrition 2Health News:Bally Total Fitness Emerges From Chapter 11 and Closes Transaction with Harbinger Capital Partners Funds 2Health News:Bally Total Fitness Emerges From Chapter 11 and Closes Transaction with Harbinger Capital Partners Funds 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: